Additional protective or risk factors may be required in these patients to influence the clinical outcome of COVID-19, such as age or the nature of the AAN-I-IFNs (neutralizing IFNω and/or the 12 IFNα subtypes). The gene discussed is IFNA17; the disease is COVID-19.